Buy Max Healthcare Ins: IIFL Securities's Target Price Rs 1000

IIFL Securities has recommended a buy call for Max Healthcare Institute at a current market price of Rs 973.5. The stock has been rated with a target price of Rs 1000, indicating an upside potential of approximately 2.7%. The brokerage firm's analysis suggests that Max Healthcare's strong brand presence, efficient operations, and expansion plans position it for sustained growth in the healthcare sector. Investors are advised to consider this buy call and factor in the potential for returns and growth prospects.

About Max Healthcare Ins:

Max Healthcare Institute Limited (Max Healthcare) is a leading provider of healthcare services in India. It operates a network of 17 hospitals across India, including the flagship facility in Saket, New Delhi. Max Healthcare offers a wide range of services, including medical, surgical, cardiac, oncology, and neurology. The company has a team of over 4,000 doctors and over 10,000 employees. Max Healthcare is listed on the National Stock Exchange of India (NSE) and has a market capitalization of over INR 25,000 crore (USD 3.4 billion). The company is a part of Max India Limited, a leading Indian conglomerate with interests in healthcare, insurance, and financial services.

52 Week Price Trend:

Max Healthcare Ins(NSE:MAXHEALTH)'s current market price (CMP) of Rs 973.5 indicates a significant appreciation from its 52-week low of Rs 411.9, marking a notable gain of 136%. However, it remains below its 52-week high of Rs 910, suggesting potential for further upside. Investors may consider assessing the company's fundamentals, industry trends, and market conditions before making investment decisions.

Stratzy's MOST Analysis:

MAXHEALTH has received an AA rating from Stratzy's MOST Framework, indicating a medium level of fundamental risk. This rating is based on an assessment of the company's Management, Outlook, Safety, and Trend. The AA rating suggests that MAXHEALTH has a solid management team, a positive outlook for future growth, a strong financial position, and a track record of positive performance. This rating indicates that MAXHEALTH is a relatively low-risk investment with a good potential for future returns.

Company's Fundamentals:

Max Healthcare Ins (NSE:MAXHEALTH) is currently trading at a Stock PE of 76.78, indicating that investors are willing to pay 76.78 times the company's earnings per share for each share they purchase. Its PB Ratio of 10.34 suggests that the company's market value is 10.34 times its book value. In terms of dividends, MAXHEALTH offers a Dividend Yield of 0.12%, implying that investors receive 0.12% of their investment amount as dividends each year. These metrics provide insights into the company's valuation, profitability, and dividend distribution policy.

Fundamental and Technical information provided in this blog were last updated on 17 Sep, 2024

Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.